Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2015-00301 | Registry Identifier | CTRP |
Not provided
Not provided
Not provided
technician left institution
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will look at the feasibility of using magnetic resonance fingerprinting (MRF) in children, adolescents and young adults (AYA) with and without brain tumors. This study will also look at subjects with and without neurofibromatosis type 1(NF1), a genetic disorder that affects the growth of nervous system cells. Further, it will explore potential ways of using of MRF signal measurements in children, adolescents, and young adults with brain tumors, including tissue characterization, looking at whether the treatment was effective, and finding metastasized tumors of unknown origin (occult tumors). To explore the feasibility and potential applications of MRF, this study will recruit up to 80 subjects but will stop once 10 subjects have usable data in each of six groups.
Specific Aim 1: Demonstrate the feasibility of magnetic resonance fingerprinting (MRF) in children, adolescents and young adults (AYA) with and without brain tumors.
Specific Aim 2: Characterize the MRF signature of low-grade gliomas
Specific Aim 3: Determine whether MRF can identify occult tumor in subjects with low-grade glioma.
Specific Aim 4: Determine whether MRF can identify treatment effects in low-grade gliomas.
Specific Aim 5: Explore whether common brain tumors can be differentiated by comparing pre-operative MRF signature with pathologic diagnosis.
Outline: This study will examine the feasibility of MRF in children and AYA and determine whether quantitative measures of T1 and T2 relaxation times can be derived in subjects <35 years of age. Approximately 80 subjects will be evaluated and include subgroups where MRF may be of particular utility, including children and AYA subjects with brain tumors and subjects with neurofibromatosis type 1 (NF1). Additional aims will investigate the utility of MRF in these groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NF1-associated Optic Pathway Glioma (OPG) | Experimental | Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting |
|
| NF1 without brain tumor | Experimental | Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting |
|
| Without NF1 and with brain tumor exposed to therapy | Experimental | Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting |
|
| Without NF1 and with untreated low grade brain tumors | Experimental | Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting |
|
| Without NF1 and without brain tumors |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Magnetic Resonance Imaging | Device | Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Average Duration of MRF Sequence - Feasibility | The duration of MRF sequence in minutes will be recorded as a measure of feasibility | Up to 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients With Evaluable T1 and T2 Relaxation Times on MRF Scans | Number of patients which have evaluable scans at both T1 and T2 | Up to 1 year |
| Comparison of Relaxometry MRI Scans Between Low Grade Gliomas and Healthy Brain Tissue |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of Relaxometry Values Between Tumors of Varying Pathology | Descriptive statistics will be used to identify the T1 and T2 relaxation times for tumors of different types on pre-operative MRF scan | Up to 1 year |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Deborah R Gold, MD | Case Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rainbow Babies and Children's Hospital | Cleveland | Ohio | 44106 | United States |
Protocol enrollment was 35 but data are only available for 34 participants - Study team believes one participant's scan was never completed with MRF but because the study was terminated in 2018 with no further access to data this cannot be confirmed.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | NF1-associated Optic Pathway Glioma (OPG) | Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| FG001 | NF1 Without Brain Tumor | Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| FG002 | Without NF1 and With Brain Tumor Exposed to Therapy | Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| FG003 | Without NF1 and With Untreated Low Grade Brain Tumors | Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| FG004 | Without NF1 and Without Brain Tumors | Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| FG005 | Brain Tumors of Assorted Pathology | Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Participants enrolled in study
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | NF1-associated Optic Pathway Glioma (OPG) | Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Average Duration of MRF Sequence - Feasibility | The duration of MRF sequence in minutes will be recorded as a measure of feasibility | Participants enrolled in study | Posted | Mean | Standard Deviation | minutes | Up to 1 year |
|
Up to 1 year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | NF1-associated Optic Pathway Glioma (OPG) | Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Deborah Runkin Gold | University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | 1-800-641-2422 | CTUReferral@UHhospitals.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 21, 2016 | Aug 4, 2020 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Oct 26, 2017 | Aug 4, 2020 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D009456 | Neurofibromatosis 1 |
| D001932 | Brain Neoplasms |
| D005910 | Glioma |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D017253 | Neurofibromatoses |
| D009455 | Neurofibroma |
| D018317 | Nerve Sheath Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
Not provided
Not provided
| ID | Term |
|---|---|
| D008279 | Magnetic Resonance Imaging |
| ID | Term |
|---|---|
| D014054 | Tomography |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting |
|
| Brain tumors of assorted pathology | Experimental | Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting |
|
|
| Magnetic Resonance Fingerprinting | Device | Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
|
|
Using Wilcoxon rank sum test to compare continuous variables, researchers will identify scans with significant difference in relaxometry between low-grade (composite of arms 1,3,4) and versus healthy brain tissue.
| Up to 1 year |
| Combination of Relaxometry MRI Scans Between High Grade Gliomas and Healthy Brain Tissue | Using Wilcoxon rank sum test to compare continuous variables, researchers will identify scans with significant difference in relaxometry between high-grade (arm 6) and versus healthy brain tissue. | Up to 1 year |
| Comparison of Scans of Treated and Untreated Low Grade Gliomas (LGG) | Using paired t-tests or non-parametric Wilcoxon signed rank tests, researchers will identify scans with significant differences in scans of treated and untreated tumors | Up to 1 year |
| BG001 | NF1 Without Brain Tumor | Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| BG002 | Without NF1 and With Brain Tumor Exposed to Therapy | Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| BG003 | Without NF1 and With Untreated Low Grade Brain Tumors | Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| BG004 | Without NF1 and Without Brain Tumors | Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| BG005 | Brain Tumors of Assorted Pathology | Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| BG006 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | NF1 Without Brain Tumor | Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| OG002 | Without NF1 and With Brain Tumor Exposed to Therapy | Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| OG003 | Without NF1 and With Untreated Low Grade Brain Tumors | Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| OG004 | Without NF1 and Without Brain Tumors | Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
| OG005 | Brain Tumors of Assorted Pathology | Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). |
|
|
| Secondary | Number of Patients With Evaluable T1 and T2 Relaxation Times on MRF Scans | Number of patients which have evaluable scans at both T1 and T2 | Participants enrolled in study | Posted | Count of Participants | Participants | Up to 1 year |
|
|
|
| Secondary | Comparison of Relaxometry MRI Scans Between Low Grade Gliomas and Healthy Brain Tissue | Using Wilcoxon rank sum test to compare continuous variables, researchers will identify scans with significant difference in relaxometry between low-grade (composite of arms 1,3,4) and versus healthy brain tissue. | Participants enrolled on arms 1,3 and 4. Combination of Arms 1, 3, and 4 for reporting was pre-specified in the study protocol. Each participant had a single tumor sample measured and a single normal-appearing white matter measured. | Posted | Mean | Standard Deviation | milliseconds (ms) | Up to 1 year |
|
|
|
|
| Secondary | Combination of Relaxometry MRI Scans Between High Grade Gliomas and Healthy Brain Tissue | Using Wilcoxon rank sum test to compare continuous variables, researchers will identify scans with significant difference in relaxometry between high-grade (arm 6) and versus healthy brain tissue. | Participants in arm 6 had a measurable solid portion of HGG and were used for this analysis. Each participant had a single tumor sample measured and a single normal-appearing white matter measured. | Posted | Mean | Standard Deviation | milliseconds (ms) | Up to 1 year |
|
|
|
|
| Secondary | Comparison of Scans of Treated and Untreated Low Grade Gliomas (LGG) | Using paired t-tests or non-parametric Wilcoxon signed rank tests, researchers will identify scans with significant differences in scans of treated and untreated tumors | Participants enrolled in study. Combination of Arms for reporting was pre-specified in the study protocol | Posted | Mean | Standard Deviation | milliseconds (ms) | Up to 1 year |
|
|
|
|
| Other Pre-specified | Comparison of Relaxometry Values Between Tumors of Varying Pathology | Descriptive statistics will be used to identify the T1 and T2 relaxation times for tumors of different types on pre-operative MRF scan | Not Posted | Up to 1 year | Participants |
| 0 |
| 4 |
| 0 |
| 4 |
| 0 |
| 4 |
| EG001 | NF1 Without Brain Tumor | Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). | 0 | 6 | 0 | 6 | 0 | 6 |
| EG002 | Without NF1 and With Brain Tumor Exposed to Therapy | Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). | 0 | 6 | 0 | 6 | 0 | 6 |
| EG003 | Without NF1 and With Untreated Low Grade Brain Tumors | Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). | 1 | 8 | 0 | 8 | 0 | 8 |
| EG004 | Without NF1 and Without Brain Tumors | Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). | 0 | 4 | 0 | 4 | 0 | 4 |
| EG005 | Brain Tumors of Assorted Pathology | Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting Magnetic Resonance Imaging: Patients will have a scan of soft tissue using magnetic field and radio frequency pulses. Magnetic Resonance Fingerprinting: Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2). | 1 | 6 | 0 | 6 | 0 | 6 |
Not provided
Not provided
Not provided
| D009370 |
| Neoplasms by Histologic Type |
| D009386 | Neoplastic Syndromes, Hereditary |
| D020752 | Neurocutaneous Syndromes |
| D009422 | Nervous System Diseases |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009375 | Neoplasms, Glandular and Epithelial |
Comparison of T2 values
| Wilcoxon (Mann-Whitney) |
| 0.0003 |
| Other |
This test was a two-sample test using non-parametric data. A predefined margin was not used because no gold standard exists. A p-value of less than 0.05 was considered statistically different |
Comparison of T2 values
| Wilcoxon (Mann-Whitney) |
| 0.081 |
| Other |
This test was a two-sample test using non-parametric data. A predefined margin was not used because no gold standard exists. A p-value of less than 0.05 was considered statistically different |
Comparison of T2 values
| Wilcoxon (Mann-Whitney) |
| 0.14 |
| Other |
This test was a two-sample test using non-parametric data. A predefined margin was not used because no gold standard exists. A p-value of less than 0.05 was considered statistically different |